European Psychiatry - Volume 33 - March 2016

418 / 812

S414 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
inpatient with a psychotic mixed state due to a medical condition
(neurosyphilis).
Method An inpatient with psychotic mixed state in BD was
assessed with: SCID-P, HRSD, YMRS, and a complete internisti-
cal examination, blood test exams, urinanalysis, electrocardiogram
and ecocardiogram, as well as a first level brain imagin (CT and/or
MRI). We conducted a systematic review of the literature (PubMed,
Embase, PsychInfo), using the terms “bipolar disorder”, “neu-
rosyphilis” AND “mixed state”.
Results A comprehensive diagnostic and laboratory screening
was unremarkable except for a positive venereal disease research
laboratory (VDRL). Treatment for syphilis was started and we used
olanzapine to control the psychiatric symptoms.
Discussion and conclusion The estimated annual incidence of non-
HIV STIs (sexually transmitted infections) has increased by nearly
50% during the period 1995–2008 Our case report underly,
like Barbosa et al., the need to evaluate neurosyphilis as a poten-
tial cause of behavioural and psychiatric symptoms that simulate
a psychotic mixed state of bipolar disorder. Olanzapine control
and improve the psychiatric symptomatology in neurosyphilis.
Methodological limitations, clinical implications and suggestions
for future research directions are considered.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
References
[1] Perugi G, et al. 2014.
[2] Barbosa IG, et al. 2012.
[3] Ortayli N, et al. 2014.
EV202
Monitoring of biochemicals changes
in antipsychotics and anti-depressive
therapy
A. Prifti emalli ∗ ikaj
1 Policlinic of Specialty Nr.3, Laboratory, Tirana, Albania
2 The Regional Health Authority, Tirana, Albania
∗ Corresponding author.
Objective Biochemical changes in treatment of schizophrenic and
bipolar disorders, in Albanian patients, with atypical antipsychotic
and anti-depressive drugs. Some of the adverse effects related to
their use are hyperlipidemia, hepatic enzymes, type 2 diabetes and
CK level, which may result in development of metabolic syndrome.
This study aimed to investigate a possible increase of biochemical
parameters, in patients with schizophrenia and bipolar disorders
treatedwith atypical antipsychotic and antidepressive drugs (Olan-
zapin, Risperidon, Clozapin, Antidepresiv triciclik, SSRI, SNRI).
Methods Forty subjects with schizophrenia and bipolar disorders
were evaluated, 12 women and 28 men, aged between 17 and 72
years. Blood collection of the patients was taken in our labora-
tory and this values were measure in long treatment patients, after
years of treatment. Analyses were perform in our laboratory with
autoanalysator SAT 450.
Results Evaluation after measurements showed significant dif-
ferences when comparing the mean values obtained in each
patients. The biochemical indicators of development of metabolic
syndrome measured in our study, show that is an increasement
of lipids panel, specially triglycerides and total cholesterol, also
in glucose, CK level and hepatic enzymes, presenting statistically
significant changes (P < 0.05) for prolong treatment.
Conclusion We conclude that the treatment with atypical
antipsychotic and antidepressive drugs, promoted a substantial
increasing of biochemical blood parameters. Lipids panel, hepatic
enzymes, type 2 diabetes, CK levels are observed in among subjects
evaluated.
Keywords Measurements; Biochemical parameters;
Schizophrenia; Bipolar disorders
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV203
Manic episode secondary to maca
P. Quandt ∗ Puga
1 Hospital Universitario de Canarias, Psiquiatría, La Laguna, Spain
2 Hospital Universitario Nuestra Se˜nora de Candelaria, Psiquiatría,
S/C de Tenerife, Spain
∗ Corresponding author.
Introduction Maca ( Lepidium meyenii) is a plant grown in the
Andes Mountains, formerly used for nutritional purposes. Nowa-
days is used as a nutritional supplement and energizing.
Objectives To describe a case of manic episode secondary tomaca
consumption, as an ingredient of an energizing product.
Aims To report on antidepressant properties of maca, based on a
clinical case.
Methods X. is a 27-years-old male without any psychiatric his-
tory. He came to the emergency service because of the presence of
sudden onset behavioral disorders, presenting amanic-like episode
of seven hours of evolution. His symptoms consisted in psychomo-
tor restlessness, hyperactivity, insomnia, verbose and loud speech,
hyperthymia, megalomaniac verbalizations, and unsuitable future
plans. The patient had self-awareness of his symptoms and was
self-critical with his behavior. He reported he was consuming an
energizing supplement containingmaca fromabout twoweeks ago.
Treatment with olanzapine 20mg was initiated, and the patient
remained under observation for 24 hours.
Results Symptomatology subsided completely after 24 hours.
The patient is discharged from the hospital with diagnosis of manic
episode secondary to maca, without any treatment. He was advice
to not take stimulants.
Conclusions There are studies reporting that maca plant has
antidepressant properties, associated with the activation of nora-
drenergic and dopaminergic systems, as well as the attenuation
of oxidative stress. However, more studies are needed to identify
specific compounds that produce these effects.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV204
First manic episode in a patient with a
frontal meningioma
M. Queirós ∗, J. Caseiro
1 Hospital de Magalhães Lemos, Psiquiatria, Porto, Portugal
2 Centro Hospitalar do Porto, Pedopsiquiatria e Saúde Mental da
Crianc¸ a e Adolescente, Porto, Portugal
∗ Corresponding author.
Introduction Psychiatric symptoms are common among brain
tumor patients. Meningiomas are the most common benign brain
tumors accounting for 13 to 26% of all intracranial tumors and
might present exclusively with psychiatric symptoms. To diagnose
a manic episode according to DSM-5 criteria the episode must not
be attributable to the physiological effects of a substance or to
another medical condition.
Objectives/aims Describe a case of first manic episode with a
frontalmeningioma alongwith a brief reviewof available literature.
Methods The case we report is based on information collected
from interviews with the patient and the family members as well
as from the clinical files. The literature reviewwas performed using
the PubMed database.
Results We describe the case of a 58-year-old woman presenting
with symptoms of a first manic episode with psychotic features.
There were no previous hypomanic or major depressive episodes.